Treatment of Early Nasal Polyposis With Topical Triamcinolone
![]() |
The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details. |
ClinicalTrials.gov Identifier: NCT01222871 |
Recruitment Status :
Terminated
(not enough particpants)
First Posted : October 18, 2010
Results First Posted : June 28, 2018
Last Update Posted : June 28, 2018
|
- Study Details
- Tabular View
- Study Results
- Disclaimer
- How to Read a Study Record
Condition or disease | Intervention/treatment | Phase |
---|---|---|
Nasal Polyps | Drug: Triamcinolone Drug: Saline soaked sponge | Phase 1 Phase 2 |
Study Type : | Interventional (Clinical Trial) |
Actual Enrollment : | 1 participants |
Allocation: | Randomized |
Intervention Model: | Single Group Assignment |
Intervention Model Description: | Patients will be randomized into 2 study groups, experimental and control. |
Masking: | None (Open Label) |
Primary Purpose: | Treatment |
Official Title: | Treatment of Early Nasal Polyposis With Topical Triamcinolone |
Actual Study Start Date : | July 2010 |
Actual Primary Completion Date : | July 2012 |
Actual Study Completion Date : | August 2012 |

Arm | Intervention/treatment |
---|---|
Experimental: Triamcinolone
Triamcinolone soaked nasopore dressing
|
Drug: Triamcinolone
Triamcinolone soaked nasopore dressing
Other Name: Kenalog (40) |
Placebo Comparator: Control Group
Saline soaked sponge
|
Drug: Saline soaked sponge
saline soaked sponge |
- Nasal Endoscopic Exam Findings . [ Time Frame: 2 weeks, 6 weeks, 12 weeks were not collected from any participant. ]nasal endoscopic exam findings at 2 weeks, 6 weeks and 12 weeks were not collected from any participant.

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.
Ages Eligible for Study: | 18 Years and older (Adult, Older Adult) |
Sexes Eligible for Study: | All |
Accepts Healthy Volunteers: | No |
Inclusion Criteria:
- Age > 18 years
- Patients with early nasal polyposis
Exclusion Criteria:
- Age < 18 years
- Patients with active sinus infections
- Patients on long term steroids
- Allergy or sensitivity to steroids
- Patients with Antrochoanal polyps
- Patients who received topical steroids by bio-resorbable sponge or oral steroids

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.
Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT01222871
United States, Massachusetts | |
St. Elizabeth's Medical Center, 736 Cambridge St | |
Brighton, Massachusetts, United States, 02135 |
Study Director: | Peter Catalano, MD | Steward St. Elizabeth's Medical Center of Boston, Inc. |
Responsible Party: | Peter Catalano, Chief of Otolaryngology, Steward St. Elizabeth's Medical Center of Boston, Inc. |
ClinicalTrials.gov Identifier: | NCT01222871 |
Other Study ID Numbers: |
00540 |
First Posted: | October 18, 2010 Key Record Dates |
Results First Posted: | June 28, 2018 |
Last Update Posted: | June 28, 2018 |
Last Verified: | June 2018 |
Individual Participant Data (IPD) Sharing Statement: | |
Plan to Share IPD: | Yes |
Treatment |
Nasal Polyps Nose Diseases Respiratory Tract Diseases Otorhinolaryngologic Diseases Polyps Pathological Conditions, Anatomical |
Triamcinolone Anti-Inflammatory Agents Glucocorticoids Hormones Hormones, Hormone Substitutes, and Hormone Antagonists Physiological Effects of Drugs |